SCHEMBL10179730

SCHEMBL10179730

O=C(O)[C@@H]1CCCN(CC(F)(F)F)C1

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 5/20 0.47
SLC6A11 P48066 1/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10179733 1.00 SLC6A1 (0.47) SLC6A1SLC6A11ALDH1A1CYP1A2CYP2D6
SCHEMBL25340721 0.89 NOTUM (0.43) SLC6A1CYP1A2
SCHEMBL3284922 0.89 NOTUM (0.43) SLC6A1CYP1A2
SCHEMBL17814311 0.86 SMN1; SMN2 (0.40) SLC6A1SLC6A11ALDH1A1CYP1A2CYP2D6
Hydrochloric Acid SCHEMBL28446461 0.83 BCHE (0.52) ALDH1A1HSD17B10LMNA
SCHEMBL13605164 0.83 SLC6A11 (0.47) SLC6A1SLC6A11ALDH1A1CYP1A2CYP2D6
SCHEMBL23557995 0.83 SLC6A11 (0.47) SLC6A1SLC6A11ALDH1A1CYP1A2CYP2D6
SCHEMBL20161465 0.81 S1PR5 (0.40)
SCHEMBL3212052 0.78 LMNA (0.41) CYP2C9TSHRCYP2C19LMNA
SCHEMBL10180993 0.77 SLC6A1 (0.52) SLC6A1SLC6A11ALDH1A1CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012101063-A1 N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2012-08-02 WO disclosed
WO-2012101064-A1 N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2012-08-02 WO disclosed
EP-2473499-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-07-11 EP disclosed